Company intelligence / Profile preview

Phoenix Tissue Repair

Boston, Massachusetts, United Statesx.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 1

Overview

PTR-01, an intravenously administered recombinant collagen VII protein replacement therapy for RDEB, demonstrated positive results in a Phase 2 trial. The treatment was well-tolerated over four months and led to rapid and durable wound healing with decreased pain reported by all patients who completed the study. No treatment-related serious adverse events were observed in early cohorts

Therapeutic areas: Dermatology
Modalities: Recombinant protein therapy (recombinant collagen type VII)
Industry: Biotech

Drug pipeline

1 asset

PTR-01

Phase 1/2

Indications: Recessive dystrophic epidermolysis bullosa, Dystrophic epidermolysis bullosa

Partnerships

BridgeBio Pharma, Inc. (parent/affiliate relationship)

Beyond the preview

Go deeper on Phoenix Tissue Repair.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phoenix Tissue Repair.

Explore the full profile